TY - JOUR
T1 - Impact of mammographic screening on the detection of good and poor prognosis breast cancers
AU - Esserman, Laura J.
AU - Shieh, Yiwey
AU - Rutgers, Emiel J.T.
AU - Knauer, Michael
AU - Retèl, Valesca P.
AU - Mook, Stella
AU - Glas, Annuska M.
AU - Moore, Dan H.
AU - Linn, Sabine
AU - Van Leeuwen, Flora E.
AU - Van 'T Veer, Laura J.
N1 - Funding Information:
Acknowledgments This study was supported by 5UO1CA111234 (Early Detection Research Network), the UCSF Dean’s Medical Student Summer Research Fellowship (YS) and the Dutch Genomics Initiative ‘Cancer Genomics Center’. The Dutch Association of Comprehensive Cancer Centers and Michiel Schaapveld are acknowledged for providing stage specific incidence data. The authors thank Karen Sepucha for editing the manuscript.
PY - 2011/12
Y1 - 2011/12
N2 - We sought to compare the molecular signature of node negative cancers from two cohorts 15 years apart, to determine if there is molecular evidence of increase in low and ultralow risk cancers over time. We studied the impact of age, time period of diagnosis, and mammographic screening on biology of tumors where The Netherlands Cancer Institute 70-gene prognosis signature was generated as part of 2 validation series, one retrospective (1984-1992), Cohort 1, and one prospective (2004-2006), Cohort 2. A total of 866 patients were analyzed. Regardless of time period of diagnosis, the proportion of T1, grade 1, hormone receptor positive (HR) tumors, and good prognosis by 70-gene signature significantly increases as age increases (P < 0.01). In women aged 49-60, the time period of diagnosis significantly affects the proportion of cancers that were NKI 70-gene low risk: 40.6% (67/165) compared with 58% (119/205) for Cohorts 1 and 2, respectively. This is in contrast to the absence of a significant change for women under age 40, where 25% (17/68) and 30% (17/56) were low risk in Cohorts 1 and 2, respectively. In women aged 49-60, using an ultralow risk threshold of the 70-gene signature, 10% of tumors in Cohort 1 were ultralow risk compared with 30% for women with screen-detected cancers in Cohort 2. Older age and method of detection (screening) are associated with a higher likelihood of a biologically low risk tumor. In women over age 50, biologically low risk tumors are frequent and tools that classify risk may minimize overtreatment.
AB - We sought to compare the molecular signature of node negative cancers from two cohorts 15 years apart, to determine if there is molecular evidence of increase in low and ultralow risk cancers over time. We studied the impact of age, time period of diagnosis, and mammographic screening on biology of tumors where The Netherlands Cancer Institute 70-gene prognosis signature was generated as part of 2 validation series, one retrospective (1984-1992), Cohort 1, and one prospective (2004-2006), Cohort 2. A total of 866 patients were analyzed. Regardless of time period of diagnosis, the proportion of T1, grade 1, hormone receptor positive (HR) tumors, and good prognosis by 70-gene signature significantly increases as age increases (P < 0.01). In women aged 49-60, the time period of diagnosis significantly affects the proportion of cancers that were NKI 70-gene low risk: 40.6% (67/165) compared with 58% (119/205) for Cohorts 1 and 2, respectively. This is in contrast to the absence of a significant change for women under age 40, where 25% (17/68) and 30% (17/56) were low risk in Cohorts 1 and 2, respectively. In women aged 49-60, using an ultralow risk threshold of the 70-gene signature, 10% of tumors in Cohort 1 were ultralow risk compared with 30% for women with screen-detected cancers in Cohort 2. Older age and method of detection (screening) are associated with a higher likelihood of a biologically low risk tumor. In women over age 50, biologically low risk tumors are frequent and tools that classify risk may minimize overtreatment.
KW - Breast cancer
KW - Mammographic screening
KW - NKI 70-gene prognosis signature
KW - Node negative cancers
UR - http://www.scopus.com/inward/record.url?scp=82255191703&partnerID=8YFLogxK
U2 - 10.1007/s10549-011-1748-z
DO - 10.1007/s10549-011-1748-z
M3 - Review article
C2 - 21892702
AN - SCOPUS:82255191703
SN - 0167-6806
VL - 130
SP - 725
EP - 734
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -